New drug trial targets Tough-to-Treat lung cancers
NCT ID NCT07016230
Summary
This study is testing an experimental drug called tarlatamab in patients with advanced small-cell lung cancer and other aggressive neuroendocrine cancers that have worsened after standard treatments. The main goal is to see how well the drug works and to understand why some patients might respond while others do not. About 40 participants will receive the drug by IV every two weeks and provide blood and tumor samples to help researchers learn more.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC/LOCALLY ADVANCED SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
RECRUITINGVillejuif, France
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.